Alvotech (ALVO) Expected to Announce Earnings on Wednesday

Key Points

• Alvotech is expected to announce its Q2 2025 earnings on August 13th, with analysts predicting a loss of ($0.06) per share and revenue of $120.51 million.
• Recently, UBS Group downgraded Alvotech's target price from $16.00 to $14.00 but maintained a "buy" rating for the stock.
• Goldman Sachs Group significantly increased its stake in Alvotech by 40.9% during the first quarter, now holding shares worth approximately $352,000.

Alvotech (NASDAQ:ALVO - Get Free Report) is expected to issue its Q2 2025 quarterly earnings data before the market opens on Wednesday, August 13th. Analysts expect the company to announce earnings of ($0.26) per share and revenue of $120.51 million for the quarter.

Alvotech Price Performance

ALVO traded down $0.73 during trading on Thursday, hitting $8.24. 1,221,401 shares of the stock traded hands, compared to its average volume of 213,819. The firm has a market capitalization of $2.48 billion, a P/E ratio of 22.26 and a beta of 0.11. The firm has a 50-day moving average of $9.14 and a 200 day moving average of $10.02. Alvotech has a 12-month low of $7.35 and a 12-month high of $13.70.

Institutional Investors Weigh In On Alvotech

Institutional investors and hedge funds have recently modified their holdings of the stock. Invesco Ltd. lifted its position in shares of Alvotech by 37.3% in the 2nd quarter. Invesco Ltd. now owns 32,398 shares of the company's stock worth $295,000 after purchasing an additional 8,794 shares during the period. Goldman Sachs Group Inc. lifted its position in shares of Alvotech by 40.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 36,444 shares of the company's stock worth $352,000 after purchasing an additional 10,573 shares during the period. Finally, Geode Capital Management LLC lifted its position in shares of Alvotech by 0.7% in the 2nd quarter. Geode Capital Management LLC now owns 230,291 shares of the company's stock worth $2,100,000 after purchasing an additional 1,574 shares during the period.

Analyst Upgrades and Downgrades

Separately, UBS Group dropped their target price on shares of Alvotech from $16.00 to $14.00 and set a "buy" rating for the company in a research report on Friday, July 18th.

Alvotech Company Profile

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass.